Subscribe to NRx Newsletter

Investors / Media

Read the latest news about our company, medicines, and pipeline.

View our Corporate Presentation

Highlight Articles

Featured image
Aug. 15, 2022
Press Releases
NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise

Company to Host Conference Call and Webcast August 15, 2022, at 8:30am ET RADNOR, Pa., August 15, 2022 — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), (“NRx Pharmaceuticals” or the “Company”), a clinical-stage […]

Continue Reading
Featured image
Jul. 13, 2022
Press Releases
NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director

Extensive experience in Law, Finance, and Management of Public and Private Biotechnology Companies Proven track record of creating value for shareholders National Science Board Presidential Appointee, 2018-2024 Former roles at […]

Continue Reading
2nd quarter financial results3PLAccelerated RecoveryACTIV-3ACTIV-3bActive3bAcute Respiratory Distress SyndromeAcute Respiratory FailureAdaptive Platform Trial DesignAnthony S Fauci MDARDSAviptadilAvitpadilBARDABig Rock PartnersbiobuzzBioConnect Virtual ConferenceBiotechBipolar DepressionBNP ParibasBoosterBreakthrough Therapy DesignationBRilifeBRILife®BTDCAHCardinal HealthCEOCEO updateCFOCH HealthChaim HurvitzCheddar NewsChief Executive OfficerChief Financial OfficerClinical Trialsclinical updateClosing BellCOID-19Commercial ForumlationCompassionate CareconferenceCovidCovid-19COVID-19 SurvivalCOVID-AIVCovid19Critical COVID-19CromosCytokine IL-6Cytokine StormCytokinesDal BoscoDaniel JavittData Safety Monitoring BoardDeltaDelta VariantDenk PharmadepressionDirectorDisease preventionDisease prevention & Control SummitDr YoDr. Sami SaidDr. Shmuel YitzhakiDry-powder InhalerDSMBEAPEkaterine TikaradzeEmegency Use AuthorizationEmergency UseEmergency Use Authorizationerectile dysfunctionEUAEuropean QPExpanded AccessFast TrackFDAFDA EmeFDA Emergency Use AuthorizationFDA Module 3Federal Right to Try ActFinancial ResultsFox BusinessGeorgiaGeorgia Society of PhysiciansGeorgian Ministry of HealthGILDGileadGovernment of LuxembourgH.C. Wainwright & Co.HC WainwrightHC Wainwright Annual Global Investment ConferenceHC Wainwright Global Investment ConferenceHigh Flow NasalHoustonHouston MethodistHouston Methodist JC Walkter Jr Transplant CenterI-Spyi24 NewsICUIIBRIL-6 CytokineInhaled AviptadilIQVIQVIAIra StrassbergiSpyIsraelIsrael Institute of Biological ResearchIV ZYESAMI®J. Georges YoussefJ&JJihad Georges YoussefJihad Georges Youssef MDJihad Geroges YoussefJonathan JavittJournal of Infectious Diseases and TreatmentlawsuitLuxembourgLuxembourg Ministry of the EconomyMannkindMDMental HealthMNKDMolnupiravirNanoPassNASDAQNation of GeorgiaNational Institutes of HealthNDA ZyesamiNeedhamNehpron PharmaceuticalsNephronNephron PharmaceuticalsNeuropsychiatryNIAIDNIHNRXNRx BriLife COVID VaccineNRx Business UpdateNRx EarningsNRx PharmaNRx PharmaceuticalsNRX-100NRX-100/101NRX-101NRX101NRXPOmicronOrphan Drug DesignationPandemicPeptidesPharmacovigilancePhase 2presentationPrivate PlacementProf Jonathan JavittProf Jonathan Javitt MD MPHPsychedelicsPsychiatric CarePsychiatryPTSDQ1 EarningsQ2 EarningsQ3 Finaincial ResultsQP AuditorQP DeclarationQuantum Leap HealthcareRemdesivirRespiratory Distress RatioRespiratory FailureRichard G Lugar Center for Public HealthRichard Luger CenterRIght to TryRightToTryRLF-100RLF-100_002Robert BesthofRTTSami SaidSar-CoV-2Sars-CoV-2serotoninSeth Van VoorheesSever COVID-19Stephen WillardSuicidal DepressionSuicidalityTechnosphereTESICOTreasurerUCIUkraineUS Food and Drug AdministrationUSFDAVaccineVaccine TrialVaccine TrialsVasoactive Intestinal PeptideVekluryVIPVirologywebcastZYESAMIZYESAMI®ZYESAMI® (aviptadil)ZYESAMI™ZYESAMI™ INDZysamiZYSAMI®ZYSAMI® (aviptadil)